Bobcat339

TargetMol
Product Code: TAR-T5198
Supplier: TargetMol
CodeSizePrice
TAR-T5198-5mg5mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5198-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5198-10mg10mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5198-25mg25mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5198-50mg50mg£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5198-100mg100mg£382.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Bobcat339 is a novel cytosine-based TET enzyme inhibitor (IC50s: 33/73 uM for TET1/2), but not DNMT3a, does not inhibit the DNA methyltransferase DNMT3a.
CAS:
2280037-51-4
Formula:
C16H12ClN3O
Molecular Weight:
297.74
Pathway:
Chromatin/Epigenetic
Purity:
0.98
SMILES:
Nc1nc(=O)n(cc1Cl)-c1cccc(c1)-c1ccccc1
Target:
DNA Methyltransferase

References

Shi Q, Liu R, Chen L. Ferroptosis inhibitor ferrostatin-1 alleviates homocysteine-induced ovarian granulosa cell injury by regulating TET activity and DNA methylation. Molecular Medicine Reports. 2022, 25(4): 1-9 Chua GNL, et al. Cytosine-Based TET Enzyme Inhibitors. ACS Med Chem Lett. 2019 Jan 31;10(2):180-185. Xu X, Yuan X, Ni J, et al. MAGI2?AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2. Journal of Cellular Physiology. 2021, 236(2): 1116-1130 Xu X, Yuan X, Ni J, et al. MAGI2?AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2[J]. Journal of Cellular Physiology. 2021, 236(2): 1116-1130. Shi Q, Liu R, Chen L. Ferroptosis inhibitor ferrostatin?1 alleviates homocysteine?induced ovarian granulosa cell injury by regulating TET activity and DNA methylation. Molecular Medicine Reports. 2022, 25(4): 1-9.